Ford M S, Nie Z, Whitworth C, Rybak L P, Ramkumar V
Department of Pharmacology, Southern Illinois University School of Medicine, Springfield 62794, USA.
Hear Res. 1997 Sep;111(1-2):143-52. doi: 10.1016/s0378-5955(97)00103-2.
In a previous study, we have demonstrated the presence of two adenosine receptor (AR) subtypes, namely A1 and A3AR, in the chinchilla cochlea. One or both of these receptors couple to activation of antioxidant enzymes, with resulting decreases in lipid peroxidation. The chemotherapeutic agent, cisplatin, was shown to produce ototoxicity within a few days of administration presumably by generating reactive oxygen species (ROS) and thereby increasing lipid peroxidation. In this study, we focused on whether lipid peroxidation induces hearing loss by assessing the cochlear antioxidant defense system over a shorter time period (24 h) following cisplatin administration. Cisplatin was administered to anesthetized chinchillas by round window membrane application and hearing loss was determined by compound action potential (CAP) and endocochlear potential (EP) 24 and 72 h post-treatment. Elevations in CAP thresholds in response to click and to 2, 4, 8 and 16 kHz tones and decreases in EP were obtained within 24 h of cisplatin treatment. These changes persisted for at least up to 72 h. Measurements of antioxidant enzymes indicate no change in the activities of superoxide dismutase, catalase or glutathione peroxidase, either 24 or 72 h following cisplatin treatment. The levels of malondialdehyde obtained at these time points were equivalent to those obtained from the controls. Furthermore, no difference in cochlear morphology was detectable by scanning electron microscopy at the basal, middle or apical turns of the cochlea within 24 h. By 72 h, however, losses in both inner and outer hair cells were observed in the basal and middle turns of the cochlea. A major finding of this study is that exposure to cisplatin led to a 5-fold up-regulation of [125I]N6-2-[4-amino-3-phenyl]ethyladenosine binding in the cochlea within 24 h, reflecting increases in expression of AR(s) in this tissue. These data indicate a dissociation between cisplatin acute (within 24 h) ototoxicity and lipid peroxidation. Furthermore, up-regulation of AR(s) may represent a rapid compensatory mechanism by the cochlea to counter the toxic effects of increased ROS generated by cisplatin.
在先前的一项研究中,我们已证实在灰鼠耳蜗中存在两种腺苷受体(AR)亚型,即A1和A3AR。这些受体中的一种或两种与抗氧化酶的激活相关联,从而导致脂质过氧化作用降低。化疗药物顺铂在给药后的几天内会产生耳毒性,可能是通过产生活性氧(ROS),进而增加脂质过氧化作用。在本研究中,我们通过评估顺铂给药后较短时间段(24小时)内的耳蜗抗氧化防御系统,来关注脂质过氧化是否会导致听力损失。通过圆窗膜给药将顺铂给予麻醉后的灰鼠,并在治疗后24小时和72小时通过复合动作电位(CAP)和内淋巴电位(EP)来测定听力损失。在顺铂治疗后24小时内,观察到对短声以及2、4、8和16千赫兹纯音的CAP阈值升高以及EP降低。这些变化至少持续到72小时。抗氧化酶的测量结果表明,在顺铂治疗后24小时或72小时,超氧化物歧化酶、过氧化氢酶或谷胱甘肽过氧化物酶的活性均无变化。在这些时间点测得的丙二醛水平与对照组相当。此外,在24小时内通过扫描电子显微镜在耳蜗的基部、中部或顶部螺旋处未检测到耳蜗形态的差异。然而,到72小时时,在耳蜗的基部和中部螺旋处观察到内、外毛细胞均有损失。本研究的一个主要发现是,暴露于顺铂会在24小时内导致耳蜗中[125I]N6-2-[4-氨基-3-苯基]乙基腺苷结合上调5倍,这反映了该组织中AR表达的增加。这些数据表明顺铂急性(24小时内)耳毒性与脂质过氧化之间没有关联。此外,AR上调可能代表耳蜗的一种快速补偿机制,以对抗顺铂产生的增加的ROS的毒性作用。